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and 7 of this journal under one cover and under three
general aings of leukaemia, biology and lymphoma. Their
reviews cover a broad spectrum ofaspects ofthese dis in
considerable detail.
On the whole, the individual reviews are authoritative and
clearly written and the list of contributors is impressive. A
criticism of the way in which the book is structured is the
fact that it has been done by disease rather than by the
subject matter of the reviews. For example, there are
several excellent review articks on various aspects of cell
cycle kinetics and cytogenetics and their relationship to out-
come in leukaemia and lymphoma. These various reviews
could have been more sensibly grouped together. The chapter
by Boklhari et al. on cell cyce parameters as predictors of
prognosis in AML demonstrates the correlation of cell ccle
kinetics with outcome, and similar subjects are covered in the
chapter by Tusenius et al. in non-Hodgkin's lymphoma and
also in the chapter on proliferating cell nuclear antigen
(PCNA) by Keim and Hanash. This last chapter proviles an
exceent prescripon of PCNA backed up by a description
of its putative function as a stabiliwr of DNA polymerase.
The changes in the nuclear distribution of PCNA in the cell
cycle are also ckarly described and interesting data are pre-
sented on the relationship between PCNA expression and
clinical parameters such as the incidence of relapse in
patients with ANLLI.
Tusenius et al. review the role of various proliferation
indic iling assesment of mitotic index, transferrin
receptor, the Ki-67 antigen and nucleolar organiser regions.
The chapter descibes wel the potential limitations of this
kind of approach, although unforttely appears too arly
to include recent data from the South-West Oncology Group
prospective study idicating the independent prognostic value
of Ki-67 expression in aggressive lymphoma.
The various chapters on cytogenetic abnormalities and on
their molcular counterparts are also individually ckar but
could have been more sensibly grouped into one section of
the book. The volume also includes a number of clnical
papers of interest.
Ljungman et al. provide an overview of the role of bone
marrow tranWlantation in acute non-lymphoblastic leu-
kaemi
The article is cearly written and well balanc, emphasis-
ing the need for prospective clnical studies to assess its true
value and emphasising the importance of all unrelated donor
transplants being registered.
Johnson and Rohatiner's chapter on the role of high-dose
therapy in folliular lymphoma gives a good overview of
current experience, although it fails to emphasis that com-
parisons between various transplant and non-tansplant
series in this disease are etremely difficult because of incon-
itencies in histological interpretation of the subtypes of
folwular lymphoma. Furthermore, the chapter fails to
emphasise the need for prospective randomised studies in this
dsease.
Other chapters include descriptions of rare clinical entities
in ing splenk lymphoma with villous lymphocytes, mas-
tocytosis and coexent non-Hodgkin's lymphoma and
myelopreliferative disorders, sinus histiocytosis and post-
tansplant lymphoma. Again, all of these provide excellent
reviews by recognised experts.
OveralL this volume provides an interesting collection of
review article on a somewhat diverse subject matter in the
field of leukaemia and lymphoma. Since the articls are
derived from reviews in ajournal they inevitably flkct issues
regrded as important at the time ofwriting and therefore do
not easily fall into neat groupings for a book. Because of this
it is difficult to detemine exactly who is likcely to be interest-
ed in having this kid of volume other than those people
who are liely to read the journal in any case. Nevertheless,
the quality of the authorship and of the articles is on the
whole excllent, and for this reason alone it should be recom-
mended.
J.W. Sweetenham
Figra~ (r_metHHG-CSF) in C1ncal Pactice. Ba.c and
C~aI Oacology Series/5
Edited by G. Morstyn & T.M. Dexter, New York: Marcel
Dekier Inc., 1993, 368pp. $125.00.
Filgrastim in Clinical Practice is the fifth volume in the Basic
and Clinical Oncology series edited by Bruce Cheson.
Granulocyte colony-stimulating factor (G-CSF) was the first
human haemopoietic growth factor to be introduced into
clinical practice; 'Filgastim' is its generic name. Short
chapters on the biology, biochemistry and pharmacology are
included. Other chapters cover the role of G-CSF in treating
patients with chronic neutropenia and in ameliorating
neutropenia with reduction in the incidence of infection fol-
lowing intensive chemotherapy. The use of G-CSF in
mobilisng peripheal blood progenitor cells for haemopoietic
rescue following myeloablative chemotherapy is the subject
of a further chapter, and the final pages cover economic,
social and practical aspects of adminitation.
The chapters are relatively short and do not provide an
extensive review of the literature, and inevitably in a book of
this nature the assessment ofpublished work is 2-3 years out
of date. However, the book does provide the clinician with
important basic information on the use of G-CSF in the
clinic. Although one ofthe editors and several of the authors
are Amgen Inc. staff, the book does provide a reasonably
alanced view of the clinical role of G-CSF. However, any
economic advantage is eroding and its exact role in cinical
practice is changing with time. This book does provide the
clinician with a useful introduction to the clnical uses of
G-CSF, but in view of the expense of the agent the reader
should be advised that specific indications for its use require
continuing rea t in the light of new research defining
the role of intensive chemotherapy, growth factors and
haemopoietic stem cel rescue.
D. Crowther
D;isg.~ of Coloectal so Ovarian Card.omaA t
of I Tec,ogy
Edited by R.T. Maguire & D. Van Nostrand, New York:
Marcel Dekker, 1992, 260pp.
This book is one of a series on targeted diagnosis and
therapy which focuses on individual products or strategy for
targeted therapy. The generation and characterisation of the
monoclonal antibody B72.3 as well as the extensive pre-
clinical and clinical data are reviewed in some detail. This is
one of the most widely studied anti-tumour monoclonal
antibodies and binds a high molcular weight mucin-like
glycoprotein frequently expressed by common epithelium-
derived malignanies such as those of the colon, ovary, lung
and breast. It was generated in 1981 by conventional hy-
bridoma technology utilising the membrane fraction of cells
derived from breast cancer metastases as the immunogen.
Since then a vast number ofpreclinical and clinical data have
been generated and the antibody has been modified by ug
the techniques of antibody engineering.
The initial chapter is an excellent historical review of
radioimmunoimaging with good sections on the relative
merits ofdifferent labelling agents and some discussion ofthe
future prospects for this technology. The chapter on the
initial generation, characterisation and preclnical testing is
authoritative and indicates the typical development of
antibodies from isolation to clinical application. The major
portion of the book concentrates on the use of B72.3 in
colorectal cancer imaging, and these chapters are likewise
valuable, although some of the data are repetitive, with
chapters describing different groups, experience of imaging
with this antibody. Although a straightforward overview
might have been more helful, this is, to some extent, pro-
vided by a chapter on a multicentre trial. Overall, the book
suggests that radioimmunoimaging with this antibody has
sensitivity and specificity comparable to conventional